Prognostic utility of a semiquantitative spinal deformity index

被引:111
作者
Crans, GG [1 ]
Genant, HK
Krege, JH
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] Univ San Francisco, Osteoporosis & Arthritis Res Grp, San Francisco, CA 94117 USA
[3] Synarc Inc, San Francisco, CA 94105 USA
关键词
osteoporosis; spinal deformity index; vertebral fracture; risk assessment;
D O I
10.1016/j.bone.2005.04.003
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The semiquantitative spinal deformity index (SDI) is a summary measure of the vertebral fracture status of the spine incorporating both the number and severity of vertebral fractures. For each vertebra, a visual semiquantitative grade of 0, 1, 2, or 3 is assigned for no fracture or mild, moderate, or severe fracture, respectively, and the SDI is calculated by Summing the fracture grades of all vertebrae (T4 to L4). We investigated the effect of prevalent vertebral fracture number and severity, as integrated by the SDI, on 3-year vertebral fracture risk by performing logistic regression modeling with data from the MORE trial. There was a striking linear relationship between baseline SDI and the model-based vertebral fracture risk estimates, with a near-perfect correlation (r = 0.98, P < 0.001). However, the SDI may be overly simplistic, as a given SDI value can be attained through differing vertebral fracture scenarios (i.e., an SDI of 3 call be realized three ways), each corresponding to potentially different vertebral fracture risk. To address this issue, a second, more complex model was constructed that included individual predictor variables for number of mild, number of moderate, and number of severe prevalent vertebral fractures. The model-based risk estimates for vertebral fracture using the SDI and the more complex model were highly correlated (r = 0.91, P < 0.001), giving almost identical values up to an SDI of 5. Thus, for most clinical scenarios, it is not necessary to consider the particular fracture configuration that led to a given SDI score for predicting a patient's future vertebral fracture risk. These results validate the SDI as ail accurate tool for assessing future vertebral fracture risk; patients with greater baseline SDI had greater future risk for vertebral fractures. (c) 2005 Elsevier Inc. All lights reserved.
引用
收藏
页码:175 / 179
页数:5
相关论文
共 11 条
[1]
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis [J].
Bjarnason, NH ;
Sarkar, S ;
Duong, T ;
Mitlak, B ;
Delmas, PD ;
Christiansen, C .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (11) :922-930
[2]
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial [J].
Delmas, PD ;
Genant, HK ;
Crans, GG ;
Stock, JL ;
Wong, M ;
Siris, E ;
Adachi, JD .
BONE, 2003, 33 (04) :522-532
[3]
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].
Ettinger, B ;
Black, DM ;
Mitlak, BH ;
Knickerbocker, RK ;
Nickelsen, T ;
Genant, HK ;
Christiansen, C ;
Delmas, PD ;
Zanchetta, JR ;
Stakkestad, J ;
Glüer, CC ;
Krueger, K ;
Cohen, FJ ;
Eckert, S ;
Ensrud, KE ;
Avioli, LV ;
Lips, P ;
Cummings, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645
[4]
VERTEBRAL FRACTURE ASSESSMENT USING A SEMIQUANTITATIVE TECHNIQUE [J].
GENANT, HK ;
WU, CY ;
VANKUIJK, C ;
NEVITT, MC .
JOURNAL OF BONE AND MINERAL RESEARCH, 1993, 8 (09) :1137-1148
[5]
Hosmer D W., 1989, Applied Logistic Regression, P135
[6]
ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS - SYNOPSIS OF A WHO REPORT [J].
KANIS, JA ;
ALEXEEVA, L ;
BONJOUR, JP ;
BURKHARDT, P ;
CHRISTIANSEN, C ;
COOPER, C ;
DELMAS, P ;
JOHNELL, O ;
JOHNSTON, C ;
KANIS, JA ;
KHALTAEV, N ;
LIPS, P ;
MAZZUOLI, G ;
MELTON, LJ ;
MEUNIER, P ;
SEEMAN, E ;
STEPAN, J ;
TOSTESON, A .
OSTEOPOROSIS INTERNATIONAL, 1994, 4 (06) :368-381
[7]
PREVALENCE AND INCIDENCE OF VERTEBRAL DEFORMITIES [J].
MELTON, LJ ;
LANE, AW ;
COOPER, C ;
EASTELL, R ;
OFALLON, WM ;
RIGGS, BL .
OSTEOPOROSIS INTERNATIONAL, 1993, 3 (03) :113-119
[8]
Riggs BL, 1995, BONE S5, V17, P505
[9]
Efficacy of risedronate on clinical vertebral fractures within six months [J].
Roux, C ;
Seeman, E ;
Eastell, R ;
Adachi, J ;
Jackson, RD ;
Felsenberg, D ;
Songcharoen, S ;
Rizzoli, R ;
Di Munno, O ;
Horlait, S ;
Valent, D ;
Watts, NB .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (04) :433-439
[10]
Risedronate prevents new vertebral fractures in postmenopausal women at high risk [J].
Watts, NB ;
Josse, RG ;
Hamdy, RC ;
Hughes, RA ;
Manhart, MD ;
Barton, I ;
Calligeros, D ;
Felsenberg, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (02) :542-549